688085 Shanghai Sanyou Medical Co., Ltd
- 18.80
- 0.000.00%
Shanghai Sanyou Medical Co., Ltd News
Sanyou Medical (688085): The impact of collection has passed, and performance has entered a period of growth
Event: On April 26, 2024, Sanyou Medical released the 2023 Annual Report and the 2024 Quarterly Report: In 2023, the company achieved revenue of 460 million yuan, a year-on-year decrease of 29.08%; achieved net profit
Express News | Sanyou Medical: Plans to buy shares in Mizuki Tianpeng and Shanghai is also looking at investment shares
Sanyou Healthcare (688085.SH): Net loss of 2,095,800 yuan in the first quarter
Gelonghui, April 25 | Sanyou Medical (688085.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 86.4293 million yuan, a year-on-year decrease of 46.26%; net profit attributable to shareholders of listed companies - 2,0955,800 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,9516 million; and basic earnings per share - 0.01 yuan.
Sanyou Medical (688085.SH): The actual controller increased its total holdings by 25.20.28 million yuan and completed the increase in shares
Gelonghui March 20 | Sanyou Medical (688085.SH) announced that as of March 20, 2024, the company's actual controllers, Mr. Xu Nong, Mr. Michael MingyanLiu (Liu Mingyan), and Mr. DavidFan (Fan Xianglong), increased their holdings by a total of 25.202,800 yuan, increasing their holdings by 1,597,464 shares, accounting for 0.64%. Among them, Mr. Xu Nong increased his holdings of the company's shares by 1,043,387 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.42% of the company's total share capital, with an increase of 1,600
Sanyou Medical (688085.SH): The overall number of terminal surgeries has further increased, and the number of products shipped has increased markedly
Gelonghui, March 19 | Sanyou Medical (688085.SH) said on the interactive platform that in 2023, due to the implementation of the national procurement of high-value spinal consumables, the company's spinal product terminal admission price dropped sharply, leading to a decline in the company's operating income and net profit. However, the company's sales team actively implemented the company's sales plan and used collection to enter the company's sales gap area to increase terminal hospital coverage. The company's overall terminal operation volume further increased, and the number of products shipped increased markedly. In the future, the company will continue to strengthen therapeutic innovation and sales expansion, continue to deepen the decline in sales channels, and actively expand the international market
Sanyou Medical (688085.SH): Actual controller increases shareholding
Ge Longhui, Feb. 26 | Sanyou Medical (688085.SH) announced that as of February 26, 2024, Mr. Xu Nong had increased his holdings of the company's shares by 623,240 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.25% of the company's total share capital, with an increase of 9.1083 million yuan; Mr. Michael MingyanLiu (Liu Mingyan) increased his holdings of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for a total share capital increase of 260,778 shares, accounting for 0.11% of the company's total share capital. 4,3297 million yuan, total increase in holdings
Science and Technology Innovation Board Evening News | Fangyuan Co., Ltd., Nanxin Technology, etc. plan to buy back Sanyou Medical and Jiete Biotech Real Controllers to increase their holdings
① The Securities Regulatory Commission held the first offline press conference in the Year of the Dragon. Currently, there are no plans for a 10-year IPO backcheck, which will greatly increase the proportion of on-site inspections of companies to be listed; ② the Science and Technology Innovation 50 Index will be adjusted regularly in the first quarter to transfer to 3 individual stocks of Jinghe Integrated, Artes, and Aviation Materials; ③ Jingjin Electric: Obtaining the target for a three-in-one electric drive assembly project in the European market from a leading global vehicle customer.
Sanyou Healthcare (688085.SH): Net profit in 2023 fell 52.2% year on year
Gelonghui, Feb. 23, 丨 Sanyou Medical (688085.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total revenue of 466.673 million yuan, a year-on-year decrease of 29.04%; R&D expenses of 6380.1 million yuan, an increase of 5.67%; R&D investment accounted for 13.85%, an increase of 4.55 percentage points over the same period last year; realized net profit attributable to the owner of the parent company after deducting non-recurring profit and loss, a year-on-year decrease of 52.20%; achieved net profit attributable to the owner of the parent company after deducting non-recurring profit and loss 6,091.31 million yuan,
Sanyou Medical (688085.SH): One of the actual controllers plans to increase the company's shares by 4 million yuan to 6 million yuan
Gelonghui, Feb. 23: Sanyou Medical (688085.SH) announced that based on confidence in the future development of the company and recognition of long-term investment value, Mr. DavidFan (Fan Xianglong), one of the actual controllers, plans to use his own capital or self-raised capital to increase the company's shares through the Shanghai Stock Exchange system from February 26, 2024 to April 30, 2024. The amount of this increase in holdings is not less than RMB 400,000 and no more than RMB 60 million.
Sanyou Medical (688085.SH): The two actual controllers plan to increase their total shares by 20 million yuan to 40 million yuan
Gelonghui, Feb. 7 | Sanyou Medical (688085.SH) announced that one of the company's actual controllers, Mr. Michael Mingyan Liu (Liu Mingyan), and one of the actual controllers, director and general manager, Mr. Xu Nong, intend to use their own capital or self-financing to increase their shares through the Shanghai Stock Exchange system from February 8, 2024 to April 30, 2024 through centralized bidding. 20 million yuan and no more than
Sanyou Medical (688085.SH): Shareholder Shanghai Yuzheng made a bulk transaction and reduced its shares by 1.35%
Gelonghui, January 29丨Sanyou Medical (688085.SH) announced that on January 29, 2024, the company received a “Notice Letter Concerning a Change in Share Equity Exceeding 1%” from Shanghai Yuzheng, the company's shareholder. From January 25, 2024 to January 29, 2024, Shanghai Yizheng reduced its holdings of the company's shares by 3.344,600 shares through bulk transactions, accounting for 1.35%.
Sanyou Medical (688085.SH): Net profit is expected to drop 50.21% to 60.7% year on year in 2023
Gelonghui, January 23丨Sanyou Medical (688085.SH) announced that according to preliminary estimates by the company's finance department, net profit attributable to the owner of the parent company is expected to be 75.0 million yuan to 95.0 million yuan in 2023. Compared with the same period last year, it is expected to decrease 95.818 million yuan to 11.5818 million yuan, a year-on-year decrease of 50.21% to 60.70%. The company expects net profit from non-recurring profit and loss attributable to owners of the parent company to be between RMB 53.0 million and RMB 65.0 million in 2023, compared with the same period last year
Deep* Company* Sanyou Medical (688085): Metal additive manufacturing of intervertebral fusion devices approved by FDA, and overseas competitiveness is expected to increase 688085
On December 15, the company issued an announcement that the metal additive manufacturing intervertebral fusion device series products have obtained US FDA510 (K) certification. The series products have obtained sales qualifications in high-end markets in Europe and the US, and the company's overseas product line layout is further advanced
Shanghai Sanyou Medical Gets US FDA's Nod to Market Intervertebral Fusion Products
Shanghai Sanyou Medical (SHA:688085) obtained clearance to market its metal additive manufacturing intervertebral fusion series products in the US. The US Food and Drug Administration's 510(K) certifi
Sanyou Medical (688085.SH): The transfer price for this inquiry is 17.60 yuan/share
Gelonghui on December 14|Sanyou Healthcare (688085.SH) announced that before this change in equity, QM5 held 45,924,340 shares of the company, accounting for 18.4841% of the company's shares. On October 18, 2023, QM5 reduced its holdings by 2,484,335 shares through bulk transactions, and on December 14, 2023, reduced its holdings by 2,484,535 shares through inquiry and transfer, for a total reduction of 4,968,870 shares, accounting for 1.9999%. After the above changes in equity, QM5 held 40,955,470 shares of the company. QM5 shareholding ratio
Sanyou Medical (688085.SH)'s metal additive manufacturing intervertebral fusion device series products obtained US FDA 510 (K) certification
Sanyou Medical (688085.SH) announced that the company recently received U.S. Food and Dr....
Sanyou Medical (688085.SH): Preliminary determination that the inquiry transfer price is 17.6 yuan/share, and the transferees are 6 investors
Sanyou Medical (688085.SH) issued an announcement. After inquiring with institutional investors, the initially determined transfer price was...
Two shareholders of Sanyou Medical (688085.SH) plan to transfer 3.674,400 shares at an inquiry price
Sanyou Medical (688085.SH) announced that it plans to participate in Sanyou Medical's pre-launch shareholder inquiry and transfer the shareholder to QM...
Sanyou Medical: It plans to use its own capital of 5 million euros to participate in the subscription of the public offering of shares of the French company Implanet
Gelonghui, December 8 | Sanyou Medical announced that the company plans to use 5 million euros of its own capital to subscribe to the public offering of shares of Implanet through its wholly-owned subsidiary Sanyou (Hong Kong) International Healthcare Holdings Limited. Before this investment, the company held 41.03% of Implanet's shares. After the completion of this investment, the company's shareholding ratio in Implanet increased to about 78.48%-85.42%. Implanet will become the company's controlling subsidiary, and Implanet will be included in the scope of the company's consolidated statements.
Oriental Securities: Pharmaceutical industry development is sustainable and optimistic about industry innovation opportunities
Gelonghui, October 30 | Orient Securities Research Report points out that in the long run, medical insurance fee control and normalized collection will continue, and enterprises need to choose new varieties and fully grasp clinical needs. Therefore, we are optimistic about enterprises with real innovation capabilities, and recommend focusing on product-side demand opportunities. In terms of medical devices, routine diagnosis and treatment continue to resume and superimposed policies and marginal relaxation. The sector is expected to receive a double attack from Davis. It is recommended to focus on Mindray Healthcare, Sanyou Healthcare, Bairen Medical, etc.; in terms of innovative drugs, research and development continues to advance under strict review, and focus on cutting-edge clinical progress. It is recommended to focus on Hengrui Pharmaceutical, Jingxin Pharmaceutical, Xinqi Pharmaceutical, etc.; CXO
Analysis
Price Target
No Data
